Health

Genentech announces updated Phase III clinical data of Etrolizumab

Genentech announces updated Phase III clinical data of Etrolizumab

Health

Genentech, a biotechnology corporation that operates as an independent unit within Roche Group, has reportedly announced the top-line results from its Phase III clinical trial of etrolizumab in patients with moderately to severely active ulcerative colitis.

Sources cite that studies assessing etrolizumab as an induction therapy demonstrated mixed results. HIBISCUS I induction clinical study in people without prior anti-TNF (Anti-tumor Necrosis Factor) treatment apparently met the primary endpoint.

On the other hand, the HIBISCUS II induction clinical study, which comprised patients without previous anti-TNF treatment, didn’t achieve its primary endpoint.

Studies assessing etrolizumab as a maintenance therapy

WITHmyDOC launches RPM@Home™ kit to aid Healthcare Professionals

WITHmyDOC launches [email protected]™ kit to aid Healthcare Professionals

Health
"

Florida-based healthcare technology company WITHmyDOC has reportedly introduced [email protected]™, a remote patient monitoring (RPM) kit. It is being speculated that the kit may revolutionize the healthcare sector.

Sources cite that [email protected]™ transmits real-time biometric data of patients to healthcare providers using a web-based intelligence platform. [email protected] provides real-time data and facilitates proactive intervention by assisting chronic care management and telehealth visits.

With the help of WITHmyDOC’s RPM platform, healthcare providers will be able to review the patient’s biometric data as regularly as required during office visits. Hence it will make it easier to spot, diagno